What is Fulcrum Therapeutics, Inc.'s (FULC) StockRank?

MoatMap's StockRank for Fulcrum Therapeutics, Inc. (FULC) is 13/100, with a Strong Sell signal. This is a composite score combining Quality (40), Value (42), and Momentum (17) factor ranks across MoatMap's 20,000+ stock universe.

Does Fulcrum Therapeutics, Inc. have an economic moat?

Fulcrum Therapeutics, Inc. (FULC) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is Fulcrum Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for Fulcrum Therapeutics, Inc. (FULC) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.

What sector is Fulcrum Therapeutics, Inc. in?

Fulcrum Therapeutics, Inc. (FULC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

FULC

STRONG SELLREMOVE

Fulcrum Therapeutics, Inc. · Healthcare · United States · $454M · Avg Vol: $9M/d

StockRank

P/E (TTM)

—

ROE

-27.1%

D/E

0.0x

Dividend %

—

Director Trades · 180d

None in 180d →

Buybacks · 180d

None in 180d →

AI CONVICTION THESIS

Fulcrum Therapeutics is a clinical-stage biotech company. It is highly speculative and subject to binary clinical trial outcomes, which violates our capital preservation principles.

COMPANY DESCRIPTION

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies for genetically defined rare diseases. The company utilizes its proprietary product engine, FulcrumSeek, to identify drug targets that can regulate gene expression to treat diseases like sickle cell disease and facioscapulohumeral muscular dystrophy (FSHD). Its competitive advantage is anchored by its advanced computational biology platform and a pipeline of first-in-class therapeutic candidates.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR
Revenue	6M	3M	80M	0	255.2%
EPS	-2.44	-1.59	-0.16	-1.18	—
Shares	52M	62M	54M	67M	+27.8%
Debt	13M	11M	9M	6M	-21.7%
Equity	199M	235M	243M	349M	20.6%
Op CF	-97M	-91M	-2M	-60M	—
Inv CF	12M	-37M	32M	31M	—
Fin CF	84M	118M	3M	169M	—

PRICE (1M)-50.0%

SMA 50SMA 200

$3.51

RSI (14)

17.7

52W High

$15.74

From 52W High

0.2%

SCORE BREAKDOWN

Quality

ROIC

-24.0%26.2

ROE

-27.1%26.7

GP/Assets

-15.5%5.7

Op. Margin

0.0%40.4

FCF/Assets

-10.3%27.5

Piotroski

—28.7

Int. Cover

—N/A

D/E Ratio

0.02x83.9

Current Ratio

34.33x98.5

Value

P/E (TTM)

—N/A

EV/EBITDA

1.1x61.6

P/FCF

—N/A

P/B

0.7x86.9

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

22%2.8

RS 6M

-81%11.3

SMA 50/200

0.75x8.0

EPS Rev 4W

—N/A

EPS Rev 12W

—N/A

EPS Improve

+43%50.3

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$454M

P/E (Forward)

-5.2x

Gross Margin

0.0%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of FULC are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
FULC	Fulcrum Therapeutics, Inc.(you)	$454M	13	STRONG SELL
FBRX	Forte Biosciences, Inc.	$425M	10	STRONG SELL
EIKN	Eikon Therapeutics, Inc.	$558M	13	STRONG SELL
OCGN	Ocugen, Inc.	$477M	9	STRONG SELL
ARVN	Arvinas, Inc.	$570M	13	STRONG SELL
MNPR	Monopar Therapeutics Inc.	$432M	17	STRONG SELL
REPL	Replimune Group, Inc.	$386M	16	STRONG SELL
TRAX	First Tracks Biotherapeutics, Inc.	$552M	10	STRONG SELL
PROK	ProKidney Corp.	$547M	9	STRONG SELL
UPB	Upstream Bio, Inc.	$453M	6	STRONG SELL

Peer medians: ROE -21.9% · P/E 25.1x · Gross margin 44.3%

Fulcrum Therapeutics, Inc. (FULC) — Stock Score Summary

Fulcrum Therapeutics, Inc. (FULC) has a MoatMap StockRank of 13/100 based on Quality (40/100), Value (42/100), and Momentum (17/100) factor scores. The current signal is STRONG SELL. Fulcrum Therapeutics is a clinical-stage biotech company. It is highly speculative and subject to binary clinical trial outcomes, which violates our capital preservation principles.

Key Financial Metrics

Price	$3.51
Market Cap	$454M
P/E (Forward)	-5.24
Price/Book	0.69
Return on Equity	-27.1%
Return on Invested Capital	-24.0%
Debt/Equity	1.76
Gross Margin	0.0%
Operating Margin	0.0%
Free Cash Flow	$-38M

Fulcrum Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Fulcrum Therapeutics, Inc.’s (FULC) StockRank?: MoatMap’s StockRank for Fulcrum Therapeutics, Inc. (FULC) is 13/100, with a Strong Sell signal. It is a composite of Quality (40), Value (42), and Momentum (17) factor ranks across MoatMap’s 20,000+ stock universe.
Does Fulcrum Therapeutics, Inc. have an economic moat?: Fulcrum Therapeutics, Inc. (FULC) has a Quality factor score of 40/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Fulcrum Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for Fulcrum Therapeutics, Inc. (FULC) is Strong Sell, based on a StockRank of 13/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Fulcrum Therapeutics, Inc. in?: Fulcrum Therapeutics, Inc. (FULC) operates in the Healthcare sector, specifically the Biotechnology industry (United States).